Auxilium Pharmaceuticals, Inc.: Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX(TM) for Dupuytren's Contracture

MALVERN, PA (MARKET WIRE) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that it has completed patient enrollment in the Company's second U.S. phase III pivotal trial (CORD I) and its Australian phase III study (CORD II) of XIAFLEX™ (clostridial collagenase for injection) for the treatment of Dupuytren's contracture. In accordance with the study design, all enrolled patients have received their first injection of either XIAFLEX or placebo. Due to the high level of interest from patients and physicians, the Company was able to exceed its enrollment targets in both studies, with greater than 300 (Source: Market Wire - Pharmaceuticals and Biotech)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Read More... [Source: MedWorm: Dupuytren's Contracture - Posted by FreeAutoBlogger]